Fatih KÖSE, Gülşen DOĞAN DURDAĞ, Şafak YILMAZ BARAN, Seda YÜKSEL ŞİMŞEK, Songül ALEMDAROĞLU, Filiz AKA BOLAT, Hüsnü ÇELİK

What is the predictive value of preoperative CA 125 level on the survival rate of type 1 endometrial cancer?

Background/aim: To investigate the utility of preoperative serum cancer antigen 125 (CA 125) levels in type 1 endometrial carcinoma (EC) as a marker for determining poor prognostic factors and survival. Material and methods: All patients with endometrial cancer, who had been treated between 2012 and 2020, were retrospectively reviewed, and finally, 256 patients with type 1 endometrium carcinoma were included in the study. The relationship between the clinicopathological characteristics, CA 125 level, and survival rates were analyzed. The cut-off value for the preoperative serum CA 125 level was defined as 16 IU/L. Results: The median serum CA 125 levels were significantly higher in patients with deep myometrial invasion, lymph node metastasis, lymphovascular space invasion, cervical stromal and adnexal involvement, advanced stage, positive peritoneal cytology, recurrence, and adjuvant therapy requirement. Serum CA 125 cut-off values determined according to clinicopathologic factors ranged from 15.3 to 22.9 IU/L (sensitivity 61%–77%, specificity 52%–73%). The disease-specific survival rate was significantly higher in patients with CA 125 levels < 16 IU/L (P = 0.047). Conclusion: The data showed that choosing a lower threshold value for the CA 125 level (16 IU/L) instead of 35 IU/L, could be more useful in type 1 EC patients with negative prognostic factors.Key words: Cancer antigen 125 (CA 125), cut-off value, endometrial carcinoma, prognosis, survival

PDF

___

1. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR et al. Cancer treatment and survivorship statistics 2019. CA:A Cancer Journal for Clinicians 2019; 69 (5): 363-385. doi: 10.3322/caac.21565
2. Ferguson SE, Olshen AB, Viale A, Barakat RR, Boyd J. Stratification of intermediate-risk endometrial cancer patients into groups at high risk or low risk for recurrence based on tumor gene expression profiles. Clinical Cancer Research 2005; 11 (6): 2252-2257. doi: 10.1158/1078-0432.CCR-04-1353
3. Colombo N, Creutzberg C, Amant F, Bosse T, GonzálezMartín A et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. International Journal of Gynecologic Cancer 2016; 26 (1): 2-30. doi: 10.1097/IGC.0000000000000609
4. Duk JM, Aalders JG, Fleuren GJ, de Bruijn HWA. CA 125: A useful marker in endometrial carcinoma. American Journal of Obstetrics & Gynecology 1986; 155 (5): 1097-1102. doi: 10.1016/0002-9378(86)90358-3
5. Patsner B, Mann WJ, Cohen H, Loesch M. Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma. American Journal of Obstetrics & Gynecology 1988; 158 (2): 399-402. doi: 10.1016/0002-9378(88)90163-9
6. Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M. Retracted: Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. The Lancet Diabetes & Endocrinology 2018; 6 (2): 95-104. doi: 10.1016/s2213-8587(17)30366-2
7. Reijnen C, Visser NCM, Kasius JC, Boll D, Geomini PM et al. Improved preoperative risk stratification with CA-125 in lowgrade endometrial cancer: a multicenter prospective cohort study. Journal of Gynecologic Oncology 2019; 30 (5): e70. doi: 10.3802/jgo.2019.30.e70
8. Chao A, Tang Y-H, Lai C-H, Chang C-J, Chang S-C et al. Potential of an age-stratified CA125 cut-off value to improve the prognostic classification of patients with endometrial cancer. Gynecologic Oncology 2013; 129 (3): 500-504. doi: 10.1016/j.ygyno.2013.02.032
9. Patsner B, Yim GW. Predictive value of preoperative serum CA125 levels in patients with uterine cancer: The Asian experience 2000 to 2012. Obstetrics & Gynecology Science 2013; 56 (5): 281. doi: 10.5468/ogs.2013.56.5.281
10. Goksedef BP, Gorgen H, Yilmaz Baran S, Api M, Cetin A. Preoperative serum CA 125 level as a predictor for metastasis and survival in endometrioid endometrial cancer. Journal of Obstetrics and Gynaecology Canada 2011; 33 (8): 844-850. doi: 10.1016/s1701-2163(16)34988-x
11. Soper JT, Berchuck A, Olt GJ, Soisson AP, Clarke-Pearson DL, Bast RC. Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma. American Journal of Obstetrics & Gynecology 1990; 163 (4): 1204-1209. doi: 10.1016/0002-9378(90)90692-z
12. Chen Y-L, Huang C-Y, Chien T-Y, Huang S-H, Wu C-J, Ho C-M. Value of pre-operative serum CA125 level for prediction of prognosis in patients with endometrial cancer. Australian and New Zealand Journal of Obstetrics and Gynaecology 2011; 51 (5): 397-402. doi: 10.1111/j.1479-828X.2011.01325.x
13. Ebina Y, Sakuragi N, Hareyama H, Todo Y, Nomura E et al. Para-aortic lymph node metastasis in relation to serum CA 125 levels and nuclear grade in endometrial carcinoma. Acta Obstetricia et Gynecologica Scandinavica 2002; 81 (5): 458- 465. doi: 10.1034/j.1600-0412.2002.810514.x
14. Hoon Chung H, Weon Kim J, Park N-H, Song Y-S, Kang S-B, Lee H-P. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstetricia et Gynecologica Scandinavica 2006; 85 (12): 1501-1505. doi: 10.1080/00016340601022777
15. Hsieh C-H, ChangChien C-C, Lin H, Huang E-Y, Huang C-C et al. Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecologic Oncology 2002; 86 (1): 28-33. doi: 10.1006/gyno.2002.6664
16. Jiang T, Huang L, Zhang S. Preoperative serum CA125: a useful marker for surgical management of endometrial cancer. BMC Cancer 2015; 15 (1): 396. doi: 10.1186/s12885-015-1260-7
17. Kim HS, Park C-Y, Lee J-M, Lee J-K, Cho C-H et al. Evaluation of serum CA-125 levels for preoperative counseling in endometrioid endometrial cancer: A multi-center study. Gynecologic Oncology 2010; 118 (3): 283-288. doi: 10.1016/j. ygyno.2010.04.018
18. Modarres-Gilani M, Vaezi M, Shariat M, Zamani N, Nourizadeh R. The prognostic role of preoperative serum CA125 levels in patients with advanced endometrial carcinoma. Cancer Biomarkers 2017; 20 (2): 135-141. doi: 10.3233/cbm-160529
19. Nikolaou M, Kourea HP, Tzelepi V, Adonakis G, Scopa CD et al. The prognostic role of preoperative serum CA 125 levels in patients with endometrial carcinoma. Journal of the Balkan Union of Oncology 2014; 19 (1): 198-202. PubMed PMID: 24659664
20. Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: Is lymphadenectomy or radiotherapy necessary? American Journal of Obstetrics & Gynecology 2000; 182 (6): 1506-1519. doi: 10.1067/ mob.2000.107335
21. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. International Journal of Gynecology & Obstetrics 2009; 105 (2): 103-104. doi: 10.1016/j. ijgo.2009.02.012
22. Atguden Z, Yildiz A, Aksut H, Yalcin SE, Yalcin Y et al. The value of preoperative CA 125 levels in prediction of myometrial invasion in patients with early-stage endometrioid-type endometrial cancer. Asian Pacific Journal of Cancer Prevention: APCJP 2016; 17 (2): 497-501. doi: 10.7314/apjcp.2016.17.2.497
23. Koper NP, Massuger LF, Thomas CM, Kiemeney LA, Verbeek AL. Serum CA 125 measurements to identify patients with endometrial cancer who require lymphadenectomy. Anticancer Research 1998; 18 (3B): 1897-1902. PubMed PMID: 9677441
24. Ünsal M, Kimyon Comert G, Karalok A, Basaran D, Turkmen O et al. The preoperative serum CA125 can predict the lymph node metastasis in endometrioid-type endometrial cancer. Ginekologia Polska 2018; 89 (11): 599-606. doi: 10.5603/ GP.a2018.0103
25. Nicklin J, Janda M, Gebski V, Jobling T, Land R et al. The utility of serum CA-125 in predicting extra-uterine disease in apparent early-stage endometrial cancer. International Journal of Cancer 2012; 131 (4): 885-890. doi: 10.1002/ijc.26433
26. Schmidt M, Segev Y, Sadeh R, Suzan E, Feferkorn I, Kaldawy A, et al. Cancer antigen 125 levels are significantly associated with prognostic parameters in uterine papillary serous carcinoma. International Journal of Gynecologic Cancer 2018; 28 (7): 1311-1317. doi: 10.1097/igc.0000000000001300
27. Todo Y, Sakuragi N, Nishida R, Yamada T, Ebina Y, Yamamoto R, et al. Combined use of magnetic resonance imaging, CA 125 assay, histologic type, and histologic grade in the prediction of lymph node metastasis in endometrial carcinoma. American Journal of Obstetrics&Gynecology 2003; 188 (5): 1265-1272. doi: 10.1067/mob.2003.318
28. DiSaia P, Creasman WT (editors). Clinical Gynecologic Oncology, sixth ed. Chicago, IL7, USA: Mosby Year Book, 2002. p. 156
29. Frost JA, Webster KE, Bryant A, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 2017; 10 (10). doi: 10.1002/14651858.CD007585.pub4
30. Helpman L, Kupets R, Covens A, Saad R, Khalifa M, Ismiil N, et al. Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer. British Journal of Cancer. 2014; 110 (3): 609-615. doi: 10.1038/bjc.2013.766